Last €72.00 EUR
Change Today +0.36 / 0.50%
Volume 234.0
CG3 On Other Exchanges
As of 7:17 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000

Fax: 908-673-9001

Celgene Corporation, together with its subsidiaries, operates as a biopharmaceutical company worldwide. The company is primarily engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The company is involved in research in various scientific areas that might deliver proprietary next-generation therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s primary commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID (inclusive of Thalidomide Celgene), ISTODAX, and azacitidine for injection (generic version of VIDAZA). The company has sales in approximately 70 countries and regions, including Europe, Latin America, the Middle East, the Asia/Pacific, and Canada. Commercial Stage Products REVLIMID (lenalidomide): REVLIMID is an oral immunomodulatory drug marketed in the United States and various international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy, as well as for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program, which is a proprietary risk-management distribution program tailored specifically to provide for the safe and appropriate distribution and use of REVLIMID. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the safe and appropriate distribution and use of REVLIMID. REVLIMID continues to be evaluated in various clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma, MDS, various lymphomas, chronic lymphocytic leukemia (CLL), other cancers, and other diseases. VIDAZA (azacitidine for injection): VIDAZA is a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS, according to the National Comprehensive Cancer Network and is marketed in the United States for the treatment of various subtypes of MDS. In 2013, the company also contracted with Sandoz AG to sell a generic version of VIDAZA, which it supplies. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia with 10% to 29% marrow blasts without myeloproliferative disorder, as well as AML with 20% to 30% blasts and multi-lineage dysplasia and has been granted orphan drug designation for the treatment of MDS and AML. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension): ABRAXANE is a solvent-free chemotherapy product, which is developed using the company’s proprietary nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. ABRAXANE is approved for the treatment of metastatic breast cancer, as well as for the treatment of non-small cell lung cancer in the United States, the European Union, Japan, and other international markets. During 2013, applications for marketing authorizations for ABRAXANE for the treatment of patients with advanced pancreatic cancer were also submitted in other countries and regions. ABRAXANE is in various stages of investigation for breast, pancreatic, and non-small cell lung cancers. POMALYST/IMNOVID1 (pomalidomide): POMALYST/IMNOVID is a proprietary, distinct, small molecule that is administered orally and modulates the immune system and other biologically important targets. POMALYST/IMNOVID received


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €72.00 EUR +0.36

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $326.88 USD +6.76
Bristol-Myers Squibb Co $51.15 USD +1.20
Regeneron Pharmaceuticals Inc $355.47 USD +9.44
Shire PLC 5,280 GBp -5.00
Thermo Fisher Scientific Inc $122.61 USD +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation CG3 Industry Range
Price/Earnings 51.8x
Price/Sales 10.2x
Price/Book 12.6x
Price/Cash Flow 41.4x
TEV/Sales 8.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at